Samsung Biologics Co Ltd (207940) — Free Cash Flow Generation Index
Samsung Biologics Co Ltd (207940) has a Free Cash Flow Generation Index of 0.82x as of September 2025. Free cash flow of ₩505.48 Billion represents 1% of operating cash flow (₩619.30 Billion). See working capital position of Samsung Biologics Co Ltd to evaluate short-term liquidity relative to the company's equity base.
FCF Generation Index
Free Cash Flow
Operating Cash Flow
Capital Expenditures
Samsung Biologics Co Ltd Free Cash Flow Generation Index (2017–2024)
Historical FCF Generation Index trend for Samsung Biologics Co Ltd across 7 annual periods. Explore 207940 operating cash to total liabilities to assess how comfortably operating cash covers total debt obligations.
Annual Free Cash Flow Generation for Samsung Biologics Co Ltd (2017–2024)
Year-by-year Free Cash Flow Generation Index for Samsung Biologics Co Ltd. For the full company profile including market capitalisation, see Samsung Biologics Co Ltd stock valuation.
| Year | FCG Index | Free Cash Flow (KRW) | Operating CF | Capital Expenditures | YoY Change |
|---|---|---|---|---|---|
| 2024 | 0.17x | ₩281.73 Billion | ₩1.66 Trillion | ₩1.38 Trillion | ▼ -49.6% |
| 2023 | 0.34x | ₩560.90 Billion | ₩1.67 Trillion | ₩1.11 Trillion | ▲ +671.1% |
| 2022 | -0.06x | ₩-56.18 Billion | ₩953.05 Billion | ₩956.84 Billion | ▼ -180.1% |
| 2021 | 0.07x | ₩33.44 Billion | ₩454.60 Billion | ₩406.25 Billion | ▼ -72.2% |
| 2020 | 0.26x | ₩53.52 Billion | ₩202.09 Billion | ₩139.66 Billion | ▲ +101.6% |
| 2019 | -16.85x | ₩-171.04 Billion | ₩10.15 Billion | ₩192.84 Billion | ▼ -610.9% |
| 2017 | -2.37x | ₩-354.99 Billion | ₩149.82 Billion | ₩494.12 Billion | — |